Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Janvilisri, Tavan ^a   Leelawat, Kawin ^b   Roytrakul, Sittiruk ^c   Paemanee, Atchara ^c   Tohtong, Rutaiwan ^a  

^a Mahidol University ^*  (Thailand)

^b RAJAVITHI HOSPITAL   (Thailand)

^c NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; GAMMA CHEMOKINE; RBAK PROTEIN, HUMAN; REPRESSOR PROTEIN; RNA BINDING PROTEIN; TUMOR ANTIGEN; UPF3B PROTEIN, HUMAN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CANCER DIAGNOSIS; CLINICAL ARTICLE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; AGED; BILIARY TRACT TUMOR; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

ADULT; AGED; ANTIGENS, NEOPLASM; BILIARY TRACT NEOPLASMS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHEMOKINES, C; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; REPRESSOR PROTEINS; RNA-BINDING PROTEINS;

EID: 84929347262     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/105358     Document Type: Article

References (34)

1. B. Blechacz and G. J. Gores, "Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment", Hepatology, vol. 48, no. 1, pp. 308-321, 2008.
2. Y. Shaib and H. B. El-Serag, "The epidemiology of cholangiocarcinoma", Seminars in Liver Disease, vol. 24, no. 2, pp. 115-125, 2004.
3. B. Sripa and C. Pairojkul, "Cholangiocarcinoma: lessons from Thailand", Current Opinion in Gastroenterology, vol. 24, no. 3, pp. 349-356, 2008.
4. T. Nakagohri, T. Kinoshita, M. Konishi, S. Takahashi, and N. Gotohda, "Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma", World Journal of Surgery, vol. 32, no. 12, pp. 2675-2680, 2008.
5. F.-T. Deng, Y.-X. Li, L. Ye, L. Tong, X.-P. Yang, and X.-Q. Chai, "Hilar inflammatory pseudotumor mimicking hilar cholangiocarcinoma", Hepatobiliary & Pancreatic Diseases International, vol. 9, no. 2, pp. 219-221, 2010.
6. B. E. Van Beers, "Diagnosis of cholangiocarcinoma", HPB, vol. 10, no. 2, pp. 87-93, 2008.
7. A. H. Patel, D. M. Harnois, G. G. Klee, N. F. Larusso, and G. J. Gores, "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis", The American Journal of Gastroenterology, vol. 95, no. 1, pp. 204-207, 2000.
8. X.-L. Qin, Z.-R. Wang, J.-S. Shi, M. Lu, L. Wang, and Q.-R. He, "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA", World Journal of Gastroenterology, vol. 10, no. 3, pp. 427-432, 2004.
9. C. Levy, J. Lymp, P. Angulo, G. J. Gores, N. Larusso, and K. D. Lindor, "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis", Digestive Diseases and Sciences, vol. 50, no. 9, pp. 1734-1740, 2005.
10. S. L. Ong, A. Sachdeva, G. Garcea et al., "Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration", Digestive Diseases and Sciences, vol. 53, no. 12, pp. 3213-3217, 2008.
11. A. Principe, M. Del Gaudio, G. L. Grazi, U. Paolucci, and A. Cavallari, "Mirizzi syndromewith cholecysto-choledocal fistula with a high CA19-9 level mimicking biliarymalignancies: a case report", Hepato-Gastroenterology, vol. 50, no. 53, pp. 1259-1262, 2003.
12. Y. Nakanuma and M. Sasaki, "Expression of blood grouprelated antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases", Hepatology, vol. 10, no. 2, pp. 174-178, 1989.
13. A. Nakeeb, P. A. Lipsett, K. D. Lillemoe et al., "Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma", The American Journal of Surgery, vol. 171, no. 1, pp. 147-152, 1996.
14. C.-Y. Chen, S.-C. Shiesh, H.-C. Tsao, and X.-Z. Lin, "The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis", Hepato-Gastroenterology, vol. 49, no. 45, pp. 616-620, 2002.
15. Y. Zhao, W.-N. P. Lee, and G. G. Xiao, "Quantitative proteomics and biomarker discovery in human cancer", Expert Review of Proteomics, vol. 6, no. 2, pp. 115-118, 2009.
16. A. I. Saeed, N. K. Bhagabati, J. C. Braisted et al., "TM4 microarray software suite", Methods in Enzymology, vol. 411, pp. 134-193, 2006.
17. H. Mi, A. Muruganujan, J. T. Casagrande, and P. D. Thomas, "Large-scale gene function analysis with the PANTHER classification system", Nature Protocols, vol. 8, no. 8, pp. 1551-1566, 2013.
18. A. Franceschini, D. Szklarczyk, S. Frankild et al., "STRING v9.1: protein-protein interaction networks, with increased coverage and integration", Nucleic Acids Research, vol. 41, pp. D808-D815, 2013.
19. J. Bruix and J. M. Llovet, "Prognostic prediction and treatment strategy in hepatocellular carcinoma", Hepatology, vol. 35, no. 3, pp. 519-524, 2002.
20. M.-H. Chen, K.-J. Lin, W.-L. R. Yang et al., "Gene expressionbased chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma", Cancer, vol. 119, no. 2, pp. 293-303, 2013.
21. T. Limpaiboon, P. Khaenam, P. Chinnasri et al., "Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma", Cancer Letters, vol. 217, no. 2, pp. 213-219, 2005.
22. U. Liengswangwong, A. Karalak, Y. Morishita et al., "Immunohistochemical expression of mismatch repair genes: a screening tool for predicting mutator phenotype in liver fluke infectionassociated intrahepatic cholangiocarcinoma", World Journal of Gastroenterology, vol. 12, no. 23, pp. 3740-3745, 2006.
23. I. Subrungruang, C. Thawornkuno, C.-P. Porntip, C. Pairojkul, S. Wongkham, and S. Petmitr, "Gene expression profiling of intrahepatic cholangiocarcinoma", Asian Pacific Journal of Cancer Prevention, vol. 14, no. 1, pp. 557-563, 2013.
24. S. Changbumrung, P. Migasena, V. Supawan, P. Juttijudata, and T. Buavatana, "Serum protease inhibitors in opisthorchiasis, hepatoma, cholangiocarcinoma, and other liver diseases", The Southeast Asian Journal of Tropical Medicine and Public Health, vol. 19, no. 2, pp. 299-305, 1988.
25. C.-Y. Chen, X.-Z. Lin, H.-C. Tsao, and S.-C. Shiesh, "The value of biliary fibronectin for diagnosis of cholangiocarcinoma", Hepato-Gastroenterology, vol. 50, no. 52, pp. 924-927, 2003.
26. H. Alkim, S. Ayaz, N. Sasmaz, P. Oguz, and B. Sahin, "Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis", Clinical and Applied Thrombosis/Hemostasis, vol. 18, no. 4, pp. 409-415, 2012.
27. Y. T. Tang, P. Emtage, W. D. Funk et al., "TAFA: a novel secreted family with conserved cysteine residues and restricted expression in the brain", Genomics, vol. 83, no. 4, pp. 727-734, 2004.
28. S. Germano, S. Kennedy, S. Rani et al., "MAGE-D4B is a novelmarker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis", International Journal of Cancer, vol. 130, no. 9, pp. 1991-2002, 2012.
29. C. E. Chong, K. P. Lim, C. P. Gan et al., "Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome", Cancer Letters, vol. 321, no. 1, pp. 18-26, 2012.
30. H. Takami, M. Kanda, H. Oya et al., "Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients", Journal of Surgical Oncology, vol. 108, no. 8, pp. 557-562, 2013.
31. T. G. Kutateladze, "Phosphatidylinositol 3-phosphate recognition and membrane docking by the FYVE domain", Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1761, no. 8, pp. 868-877, 2006.
32. S. X. Skapek, D. Jansen, T.-F. Wei et al., "Cloning and characterization of a novel Kruppel-associated box family transcriptional repressor that interacts with the retinoblastoma gene product, RB", The Journal of Biological Chemistry, vol. 275, no. 10, pp. 7212-7223, 2000.
33. J. C. Mertens, C. D. Fingas, J. D. Christensen et al., "Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma", Cancer Research, vol. 73, no. 2, pp. 897-907, 2013.
34. S. Affò, M. Dominguez, J. J. Lozano et al., "Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis", Gut, vol. 62, no. 3, pp. 452-460, 2013.